1. Clinical & Scientific Overview
Mupirocin (2% Topical & Intranasal MRSA Eradication Ointment) (TIP-MED-000256, Reference Code [12.24]) is classified under
Dermatological & Topical Antiseptic Preparations (Ch 12) as a Topical Pseudomonic Acid Antibiotic (Bacterial Isoleucyl-tRNA Synthetase Inhibitor).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.24], p. 166): T-Bact, Bactroban, Mupimet, Supirocin — Strengths & Dosage Forms: Topical Ointment / Cream: 2% w/w (5 g, 10 g, 15 g tube); Nasal Ointment (Calcium Mupirocin in paraffin base): 2% w/w.
Topical Ointment / Cream: 2% w/w (5 g, 10 g, 15 g tube); Nasal Ointment (Calcium Mupirocin in paraffin base): 2% w/w.
3. Mechanism of Action & Pharmacodynamics
Reversibly binds bacterial isoleucyl-tRNA synthetase -> blocks incorporation of isoleucine into growing peptide chains -> arrests bacterial protein and RNA synthesis (unique mechanism with no cross-resistance to systemic antibiotics).
4. Therapeutic Indications & Evidence-Supported Uses
- Localised impetigo, folliculitis, and secondary infected traumatic skin lesions caused by Staphylococcus aureus (including MRSA) and Streptococcus pyogenes
- nasal decolonisation of MRSA carriage
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Skin Infection: Apply thin film to affected area 3 times daily for 5–10 days. MRSA Nasal Decolonisation: Apply small pea-sized amount to anterior nares twice daily for 5 days. • Paediatric: Impetigo (>=2 months): Apply TDS for 5-10 days.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Standard cutaneous ointment base contains polyethylene glycol (PEG)—AVOID applying standard PEG-based ointment to large open burns or extensive denuded wounds in patients with moderate-to-severe renal impairment (PEG absorption causes nephrotoxicity). • Hepatic: No adjustment required.
Renal: Standard cutaneous ointment base contains polyethylene glycol (PEG)—AVOID applying standard PEG-based ointment to large open burns or extensive denuded wounds in patients with moderate-to-severe renal impairment (PEG absorption causes nephrotoxicity). • Hepatic: No adjustment required.
Renal: Standard cutaneous ointment base contains polyethylene glycol (PEG)—AVOID applying standard PEG-based ointment to large open burns or extensive denuded wounds in patients with moderate-to-severe renal impairment (PEG absorption causes nephrotoxicity). • Hepatic: No adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Hypersensitivity to mupirocin or polyethylene glycol. • Precautions: Restrict treatment duration to <=10 days (prolonged or widespread indiscriminate use drives high-level mupirocin plasmid resistance in hospital MRSA strains); do not use standard PEG skin ointment inside the nose or eyes (causes mucosal stinging—use paraffin-based nasal formulation for nostrils).
Key Clinical Precautions: Renal: Standard cutaneous ointment base contains polyethylene glycol (PEG)—AVOID applying standard PEG-based ointment to large open burns or extensive denuded wounds in patients with moderate-to-severe renal impairment (PEG absorption causes nephrotoxicity). • Hepatic: No adjustment required.
8. Adverse Effects Profile
- Mild localized burning, stinging, or pruritus (<2%).
- Contact sensitization, C. difficile colitis (extremely rare), PEG nephrotoxicity on extensive open wounds.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Do not mix with other topical creams/ointments (dilution instability)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Wash hands before and after applying; use for 5-10 days only; do not share towels in impetigo.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Topical Ointment / Cream: 2% w/w (5 g, 10 g, 15 g tube); Nasal Ointment (Calcium Mupirocin in paraffin base): 2% w/w.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.24] (p. 166)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.27] Povidone-Iodine (5% / 10% Antiseptic Solution, Ointment & Gargle) — Broad-Spectrum Iodophor Antiseptic & Disinfectant
- [12.28] Chlorhexidine Gluconate (0.2% Mouthwash & 4% Surgical Scrub) — Cationic Bisbiguanide Antiseptic & Disinfectant (Persistent Resid
- [12.29] Silver Sulfadiazine (1% Topical Burn Antimicrobial Cream) — Topical Heavy-Metal / Sulfonamide Burn Antimicrobial
- [12.6]-C153 Nadifloxacin — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta